Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELU) EBITDA (2020 - 2025)

Celularity (CELU) has disclosed EBITDA for 6 consecutive years, with -$23.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 43.31% to -$23.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$80.6 million, a 116.22% decrease, with the full-year FY2024 number at -$57.9 million, up 70.48% from a year prior.
  • EBITDA was -$23.1 million for Q3 2025 at Celularity, up from -$24.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $49.9 million in Q3 2021 to a low of -$93.9 million in Q3 2023.
  • A 5-year average of -$19.9 million and a median of -$19.7 million in 2025 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 1139.08% in 2021; the steepest drop was 29007.3% in 2021.
  • Celularity's EBITDA stood at -$15.0 million in 2021, then soared by 261.91% to $24.2 million in 2022, then plummeted by 69.83% to $7.3 million in 2023, then plummeted by 282.04% to -$13.3 million in 2024, then plummeted by 73.53% to -$23.1 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's EBITDA are -$23.1 million (Q3 2025), -$24.5 million (Q2 2025), and -$19.7 million (Q1 2025).